OptimizeRx (NASDAQ: OPRX) director receives 34,517 restricted stock units

Rhea-AI Filing Summary

Spangler Patrick D reported acquisition or exercise transactions in this Form 4 filing.

OptimizeRx Corp director Patrick D. Spangler received an equity award of 34,517 shares of common stock in the form of restricted stock units. The units carry a contingent right to receive OptimizeRx common stock and will vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the company’s next annual meeting of shareholders. Following this grant, he directly owns 78,732 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Spangler Patrick D

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	34,517	$0.00	--

Holdings After Transaction: Common Stock — 78,732 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 34,517 shares Grant price per share: $0.00 per share Shares owned after grant: 78,732 shares +2 more

5 metrics

RSU grant size 34,517 shares Restricted stock units of OptimizeRx common stock granted June 9, 2026

Grant price per share $0.00 per share Equity compensation grant, no cash paid by recipient

Shares owned after grant 78,732 shares Direct OptimizeRx common stock holdings following reported transaction

Vesting trigger Earlier of 1 year or next annual meeting RSUs vest in full on earlier of first anniversary of grant or next shareholder meeting

Transaction type Grant, award, or other acquisition Form 4 code A, classified as grant/award acquisition of common stock

Key Terms

restricted stock units, contingent right, annual meeting of shareholders, Form 4, +1 more

5 terms

restricted stock units financial

"Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"restricted stock units representing a contingent right to receive shares of OptimizeRx common stock."

annual meeting of shareholders financial

"will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

director financial

"Spangler Patrick D is listed as a director of OptimizeRx Corp."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spangler Patrick D

(Last) (First) (Middle)

C/O OPTIMIZERX CORPORATION

260 CHARLES STREET, SUITE 302

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OptimizeRx Corp [ OPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		34,517(1)	A	$0	78,732	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of the grant or the date of the Company's next annual meeting of shareholders.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.

	/s/ Marion Odence-Ford, by Power of Attorney	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did OptimizeRx (OPRX) report for Patrick D. Spangler?

OptimizeRx reported that director Patrick D. Spangler received a grant of 34,517 restricted stock units of common stock. These units are part of his equity compensation and represent a contingent right to receive OptimizeRx shares upon vesting, rather than an open-market purchase.

How many OptimizeRx (OPRX) shares does Patrick D. Spangler hold after this Form 4?

After the June 9, 2026 grant, Patrick D. Spangler directly owns 78,732 shares of OptimizeRx common stock. This reflects his position following the award of 34,517 restricted stock units reported in the Form 4 insider filing as a non-market compensation transaction.

What are the vesting terms of Patrick D. Spangler’s restricted stock units in OptimizeRx (OPRX)?

The 34,517 restricted stock units will vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of OptimizeRx’s next annual meeting of shareholders. Vesting must occur before the units convert into actual shares.

Was Patrick D. Spangler’s OptimizeRx (OPRX) Form 4 transaction a market purchase or sale?

The transaction was not a market purchase or sale. It was a grant of 34,517 restricted stock units at a stated price of $0.00 per share, reflecting equity compensation rather than buying or selling OptimizeRx stock on the open market.

What does the $0.00 price per share mean in the OptimizeRx (OPRX) Form 4 grant?

The $0.00 price per share indicates the restricted stock units were granted as compensation without cash payment by Patrick D. Spangler. He receives a contingent right to shares that will be delivered only if the vesting conditions described in the Form 4 footnote are satisfied.